Literature DB >> 24075785

Outcome of uterine artery embolization versus MR-guided high-intensity focused ultrasound treatment for uterine fibroids: long-term results.

V Froeling1, K Meckelburg, N F Schreiter, C Scheurig-Muenkler, J Kamp, M H Maurer, A Beck, B Hamm, T J Kroencke.   

Abstract

OBJECTIVES: To compare the long-term outcome after uterine artery embolization (UAE) versus magnetic resonance-guided high-intensity focused ultrasound (MR-g HIFU) for symptomatic uterine fibroids.
METHODS: Seventy-seven women (median age, 39.3 years; range, 29.2-52.2 years) with symptomatic uterine fibroids, equally eligible for UAE and MR-g HIFU based on our exclusion criteria underwent treatment (UAE, N = 41; MR-g HIFU, N = 36) from 2002 to 2009 at our institution. Symptom severity (SS) and total health-related quality of life (Total HRQoL) scores were assessed by the uterine fibroid symptom and quality of life (UFS-QoL) questionnaire before treatment and at long-term follow-up after UAE (median 61.9 months) and after MR-g HIFU (median: 60.7 months). Re-intervention rates were assessed for each therapy and compared.
RESULTS: Re-intervention was significantly lower after UAE (12.2%) than after MR-g HIFU (66.7%) at long-term follow-up (p<0.001). After UAE changes in SS (50 pre-treatment vs. 6.3 post-treatment) and Total HRQoL (57.8 pre-treatment vs. 100 post-treatment) were significantly better than changes in SS (42.2 pre-treatment vs. 26.6 post-treatment) and Total HRQoL score (66.4 pre-treatment vs. 87.9 post-treatment) after MR-g HIFU (p = 0.019 and 0.049 respectively).
CONCLUSIONS: Improvement of SS and Total HRQoL scores was significantly better after UAE resulting in a significant lower re-intervention rate compared to MR-g HIFU.
Copyright © 2013. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 24075785     DOI: 10.1016/j.ejrad.2013.08.045

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  23 in total

Review 1.  Updates on Uterine Artery Embolization.

Authors:  Maureen P Kohi; James B Spies
Journal:  Semin Intervent Radiol       Date:  2018-04-05       Impact factor: 1.513

Review 2.  Updates on MR-Guided Focused Ultrasound for Symptomatic Uterine Fibroids.

Authors:  Divya Sridhar; Maureen P Kohi
Journal:  Semin Intervent Radiol       Date:  2018-04-05       Impact factor: 1.513

3.  Volumetric MR-guided high-intensity focused ultrasound versus uterine artery embolisation for treatment of symptomatic uterine fibroids: comparison of symptom improvement and reintervention rates.

Authors:  Marlijne E Ikink; Robbert J Nijenhuis; Helena M Verkooijen; Marianne J Voogt; Paul J H M Reuwer; Albert J Smeets; Paul N M Lohle; Maurice A A J van den Bosch
Journal:  Eur Radiol       Date:  2014-08-13       Impact factor: 5.315

4.  Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update.

Authors:  Muneeb Ahmed; Luigi Solbiati; Christopher L Brace; David J Breen; Matthew R Callstrom; J William Charboneau; Min-Hua Chen; Byung Ihn Choi; Thierry de Baère; Gerald D Dodd; Damian E Dupuy; Debra A Gervais; David Gianfelice; Alice R Gillams; Fred T Lee; Edward Leen; Riccardo Lencioni; Peter J Littrup; Tito Livraghi; David S Lu; John P McGahan; Maria Franca Meloni; Boris Nikolic; Philippe L Pereira; Ping Liang; Hyunchul Rhim; Steven C Rose; Riad Salem; Constantinos T Sofocleous; Stephen B Solomon; Michael C Soulen; Masatoshi Tanaka; Thomas J Vogl; Bradford J Wood; S Nahum Goldberg
Journal:  Radiology       Date:  2014-06-13       Impact factor: 11.105

Review 5.  Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) Treatment of Symptomatic Uterine Fibroids: An Evidence-Based Analysis.

Authors:  G Pron
Journal:  Ont Health Technol Assess Ser       Date:  2015-03-01

6.  FIRSTT study: randomized controlled trial of uterine artery embolization vs focused ultrasound surgery.

Authors:  Shannon Laughlin-Tommaso; Emily P Barnard; Ahmed M AbdElmagied; Lisa E Vaughan; Amy L Weaver; Gina K Hesley; David A Woodrum; Vanessa L Jacoby; Maureen P Kohi; Thomas M Price; Angel Nieves; Michael J Miller; Bijan J Borah; James P Moriarty; Krzysztof R Gorny; Phyllis C Leppert; Amanda L Severson; Maureen A Lemens; Elizabeth A Stewart
Journal:  Am J Obstet Gynecol       Date:  2018-10-26       Impact factor: 8.661

7.  Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update.

Authors:  Muneeb Ahmed; Luigi Solbiati; Christopher L Brace; David J Breen; Matthew R Callstrom; J William Charboneau; Min-Hua Chen; Byung Ihn Choi; Thierry de Baère; Gerald D Dodd; Damian E Dupuy; Debra A Gervais; David Gianfelice; Alice R Gillams; Fred T Lee; Edward Leen; Riccardo Lencioni; Peter J Littrup; Tito Livraghi; David S Lu; John P McGahan; Maria Franca Meloni; Boris Nikolic; Philippe L Pereira; Ping Liang; Hyunchul Rhim; Steven C Rose; Riad Salem; Constantinos T Sofocleous; Stephen B Solomon; Michael C Soulen; Masatoshi Tanaka; Thomas J Vogl; Bradford J Wood; S Nahum Goldberg
Journal:  J Vasc Interv Radiol       Date:  2014-10-23       Impact factor: 3.464

Review 8.  The conservative and interventional treatment of fibroids.

Authors:  Alexander Stephan Boosz; Peter Reimer; Matthias Matzko; Thomas Römer; Andreas Müller
Journal:  Dtsch Arztebl Int       Date:  2014-12-22       Impact factor: 5.594

9.  Three-dimensional quantitative assessment of lesion response to MR-guided high-intensity focused ultrasound treatment of uterine fibroids.

Authors:  Lynn J Savic; Ming De Lin; Rafael Duran; Rüdiger E Schernthaner; Bernd Hamm; Jean-François Geschwind; Kelvin Hong; Julius Chapiro
Journal:  Acad Radiol       Date:  2015-07-07       Impact factor: 3.173

10.  The Focused Ultrasound Myoma Outcome Study (FUMOS); a retrospective cohort study on long-term outcomes of MR-HIFU therapy.

Authors:  Inez M Verpalen; Jolien P de Boer; Marlot Linstra; Roelien L I Pol; Ingrid M Nijholt; Chrit T W Moonen; Lambertus W Bartels; Arie Franx; Martijn F Boomsma; Manon N G Braat
Journal:  Eur Radiol       Date:  2020-02-10       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.